---
schema_version: "secwatch.filing_event.v1"
accession: "0001650664-25-000020"
form_type: "8-K"
ticker: "EDIT"
cik: "0001650664"
company_name: "Editas Medicine, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:33:16.631946+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff

## Summary
- Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.
- Cash $269.9M; operational runway into Q2 2027 includes $45-55M in restructuring costs.
- Ended reni-cel development due to failed partnership search; workforce reduced ~65%.
- On track to declare in vivo HSC and liver development candidates via gene upregulation mid-2025.
- No future quarterly earnings conference calls.

## SEC filing metadata
- accession: 0001650664-25-000020
- form_type: 8-K
- ticker: EDIT
- cik: 0001650664
- company_name: Editas Medicine, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/0001650664-25-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/edit-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001650664-25-000020
- JSON: https://secwatch.observer/filing/0001650664-25-000020.json
- Plain text: https://secwatch.observer/filing/0001650664-25-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.